Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of LYB001 SARS-CoV-2 Vaccine in Healthy Adults
NCT05137444Phase 3Unknown
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
- Start
- Jan 2022
- Primary completion
- Mar 2023
- Modality
- Recombinant Protein Vaccines
01
Overview
A Phase 3 trial of recombinant sars-cov-2 vaccine (cho cell) lyb001 in coronavirus disease 2019 (COVID-19), sponsored by Yantai Patronus Biotech Co., Ltd.. Status: unknown.
02
Drugs
recombinant sars-cov-2 vaccine (cho cell) lyb001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05137444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05137444.